Status of a real-life cohort of patients with moderate-to-severe plaque psoriasis treated with secukinumab and considerations on the use of biological agents in the Covid-19 era.
Expert Opin Biol Ther
; 20(8): 829-830, 2020 08.
Article
in English
| MEDLINE | ID: covidwho-574667
ABSTRACT
INTRODUCTION:
In light of the current Covid-19 pandemic and the ongoing, extensive debate about the use of biological agents in psoriatic patients, we felt compelled to relate our experience in the use of secukinumab in the same cohort before and during the lockdown in Italy. Areas covered Secukinumab was not discontinued, and there were no cases of confirmed infection with SARS-CoV-2 in this cohort. Expert opinion In our practice, there is no evidence favoring the discontinuation of secukinumab in these patients. We also present a brief commentary on the use of biological agents in patients with moderate-to-severe plaque psoriasis.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Psoriasis
/
Severity of Illness Index
/
Biological Factors
/
Coronavirus Infections
/
Antibodies, Monoclonal, Humanized
/
Betacoronavirus
Type of study:
Case report
/
Cohort study
/
Observational study
/
Prognostic study
Topics:
Long Covid
Limits:
Aged
/
Female
/
Humans
Country/Region as subject:
Europa
Language:
English
Journal:
Expert Opin Biol Ther
Journal subject:
Biology
/
Therapeutics
Year:
2020
Document Type:
Article
Affiliation country:
14712598.2020.1779217
Similar
MEDLINE
...
LILACS
LIS